Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0002012383-25-000635
Filing Date
2025-02-04
Accepted
2025-02-04 15:45:44
Documents
3

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 6608
2 EXHIBIT 24: POWER OF ATTORNEY PowerOfAttorney.txt EX-24 2797
3 EXHIBIT 99: ITEM 7 ITEM7.txt EX-99 535
  Complete submission text file 0002012383-25-000635.txt   11885
Mailing Address 11025 N. TORREY PINES ROAD, SUITE 140 LA JOLLA CA 92037
Business Address 11025 N. TORREY PINES ROAD, SUITE 140 LA JOLLA CA 92037 (858) 795-4220
Inhibrx Biosciences, Inc. (Subject) CIK: 0002007919 (see all company filings)

EIN.: 990613523 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-94527 | Film No.: 25587825
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 50 HUDSON YARDS NEW YORK NY 10001
Business Address 50 HUDSON YARDS NEW YORK NY 10001 (212) 810-5800
BlackRock, Inc. (Filed by) CIK: 0002012383 (see all company filings)

EIN.: 991116001 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G
SIC: 6211 Security Brokers, Dealers & Flotation Companies
(CF Office: 02 Finance)